Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer

Targeted Oncology

Volumn 9, Issue 4, 2014, Pages 367-379

  Mitrović, Olivera ^a   Čokić, Vladan ^a   Đikić, Dragoslava ^a   Budeč, Mirela ^a   Vignjević, Sanja ^a   Subotički, Tijana ^a   Gulan, Maja ^b   Radović, Snežana ^b   Furtula, Snežana ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b General Hospital U ice   (Serbia)

Author keywords

Apoptosis; FISH; HER 2; Immunohistochemistry; Molecular subtypes of breast cancer; TOP2A

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; SINGLE STRANDED DNA; TRASTUZUMAB; BCL2 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; TP53 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; ONCOGENE NEU; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL TIME; TOP2A GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BREAST TUMOR; CELL DIFFERENTIATION; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II; DNA, SINGLE-STRANDED; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919482981     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0297-2     Document Type: Article

References (29)

1. Verma S, Bal A, Joshi K, Arora S, Singh L (2012) Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India. APMIS 120:1008–1019
2. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MD, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88:491–503
3. Nielsena KV, Mullera S, Møller S, Schønau A, Balslevc E, Knoop AS, Ejlertsen B (2010) Aberrations of ERBB2 and TOP2A genes in breast cancer. Molecular oncol 4:161–168
4. Nahta R (2012) Molecular mechanisms of transtuzumab-based treatment in her2-overexpressing breast cancer. Int Scholar Res Net Oncol 2012:1–16
5. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL (1993) Topoisomerase IIa co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933–938
6. Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D (2003) Comparison of topoisomerase II alpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 77:199–204
7. Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K (2010) Topoisomerase II alpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 136:1029–1037
8. Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16:2391–2401
9. Järvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839–847
10. Bouchalova K, Trojanec R, Kolar Z, Cwiertka K, Cernakova I, Mihail V, Hajduch M (2006) Analysis of ERBB2 and TOP2A gene using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 53:393–401
11. Coon JS, Marcus E, Gupta-Bert S, Seeling S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD (2002) Amplification and over-expression of topoisomerase II-a predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Canc Res 8:1061–1067
12. Clarke BC, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991
13. Lipponen P (1999) Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer 6:13–16
14. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A (1998) Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticanc Res 18:89–97
15. Zhang GJ, Kimijima I, Abe R, Kanno M, Katagata N, Hara K, Watanabe T, Tsuchiya A (1997) Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Clin Can Res 3:2329–2335
16. Dawson S-J, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Brit J Can 103:668–675
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham L, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826
18. An 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
19. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Børresen-Dale AL, Pollack JR (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosom Cancer 45:1033–1040
20. Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16:61–70
21. Manna EDF, Teixeira LC, Alvarenga M (2006) Association between immunohistochemical expression of topoisomerase IIα, HER2 and hormone receptors and response to primary chemotherapy in breast cancer. Tumori 92:222–229
22. Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P (2002) p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 55:461–466
23. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjänen K (1995) Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177:49–55
24. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R (1999) Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 6:61–68
25. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M, Takayama S, Reed JC (1999) Prognostic significance of apoptosis regulators in breast cancer. Endo Relat Cancer 6:29–40
26. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjänen K (1996) The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122:687–692
27. Sørliea T, Peroua CM, Tibshiranie R, Aasf T, Geislerg S, Johnsenb H, Hastiee T, Eisenh MB, van de Rijni M, Jeffreyj SS, Thorsenk T, Quist H, Matesec JC, Brownm PO, Botsteinc D, Lønningg PE, Børresen-Daleb AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874
28. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L (2001) Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. British J Cancer 85:1106–1112
29. Vakkala M, Lahteenmaki K, Raunio H, Paakko P, Soini Y (1999) Apoptosis during breast carcinoma progression. Clin Cancer Res 5:319–324